Skip to main content
. 2017 Dec 11;192(1):95–103. doi: 10.1111/cei.13082

Figure 2.

Figure 2

Associations between soluble Tyro3 (sTyro3) levels and clinical features of rheumatoid arthritis (RA) patients. Patients were divided by 90% confidence interval (1·0–4·0 ng/ml) from healthy controls for sTyro3 levels calculated by spss version 19.0: patients with sTyro3 levels greater than 4·0 ng/ml were grouped into the high sTyro3 (hsTyro3) group; sTyro3 levels of all other patients were between 1·0 and 4·0 ng/ml and these patients were grouped into the normal sTyro3 (nsTyro3) group. No difference was found between female and male patients (a), treated and untreated patients (b) on sTyro3 levels. White blood cells (WBC) (c), immunoglobulin (Ig)M (d), rheumatoid factor (RF) (e), swollen joint counts (SJC) (f) and tender joint counts (TJC) (g) were increased significantly in the hsTyro3 group. The analyses were performed by Mann–Whitney U test, *P < 0·05; **P < 0·01, ***P < 0·001.